Business context and reporting period
Repligen Corporation’s Form 10-K covers the fiscal year ended December 31, 2017; the filing is an annual report, not a standalone fourth-quarter filing. Repligen supplies bioprocessing products used to manufacture biologic drugs, including Protein A ligands, chromatography columns, and filtration systems. It reports one operating segment. Spectrum, acquired August 1, 2017, expanded its filtration portfolio and contributed five months of results.
Financial performance and position
Amounts below are in millions of dollars, except per-share data and percentages.
| Metric | FY 2017 | FY 2016 |
|---|---|---|
| Total revenue | $141.2 | $104.5 |
| Gross margin | 53% | 55% |
| Operating income | $14.0 | $16.0 |
| Net income | $28.4 | $11.7 |
| Diluted EPS | $0.72 | $0.34 |
| Cash from operating activities | $17.5 | $7.5 |
| Cash and marketable securities at year-end | $173.8 | $141.8 |
| Working capital at year-end | $217.6 | $163.1 |
- Revenue grew 35% year over year. Product revenue was $141.1 million; royalty and other revenue was $0.1 million.
- By product line, 2017 revenue was $54.0 million from protein products, $49.1 million from filtration, and $36.3 million from chromatography. Filtration and chromatography growth included acquisition contributions; Spectrum generated $19.4 million of revenue after acquisition.
- Operating expenses rose 44% to $127.2 million, including SG&A of $51.5 million, up 67%. Management cited acquisition and integration costs, commercial and infrastructure expansion, and the acquired businesses’ operating expenses.
- FY 2017 non-GAAP adjusted operating income was $31.6 million; adjusted net income was $27.2 million, or $0.69 per diluted share; adjusted EBITDA was $35.1 million. These measures exclude specified acquisition, inventory step-up, amortization, and other items.
- Investing activities used $98.2 million, including $112.8 million net cash for Spectrum and $5.5 million of capital expenditures. Financing activities provided $129.9 million, mainly from the July share offering.
- Year-end current assets were $242.8 million and current liabilities $25.2 million. The company had no marketable securities at year-end 2017.
- Debt included $115.0 million principal of 2.125% convertible notes due 2021; carrying value was $99.3 million and disclosed fair value approximately $149.5 million. Long-term obligations were $126.8 million. Effective interest rate on the notes was 6.6%.
Fourth-quarter comparison
Reported Q4 2017 revenue was $41.6 million versus $25.6 million in Q4 2016, an increase of about 63%. Net income was $12.2 million versus $5.0 million, and diluted EPS was $0.27 versus $0.15. Q4 2017 included a $10.6 million income tax benefit; quarterly earnings therefore should not be read as solely reflecting operating growth.
Material changes versus prior period
- Revenue growth reflected higher filtration and chromatography volumes, full-year contributions from Atoll and TangenX, and Spectrum’s post-acquisition results. Protein product revenue decreased slightly to $54.0 million from $54.7 million.
- Gross margin declined from 55% to 53%, which management attributed to product mix, Spectrum acquired-inventory fair-value step-up charges, and investment in operating capacity.
- Operating income decreased from $16.0 million to $14.0 million despite revenue growth, as operating expenses grew faster than sales. Interest expense rose to $6.4 million with a full year of convertible-note expense.
- Net income rose substantially, but was affected by a $21.1 million income tax benefit. This included tax effects of U.S. tax reform and releases of deferred-tax valuation allowance; it is not equivalent to recurring operating earnings.
- The Spectrum acquisition was funded with approximately $122.9 million cash and $247.6 million in newly issued shares. Repligen also raised $129.3 million net through a public offering, increasing shares outstanding.
Outlook, risks, and unusual items
- Management expected 2018 operating expenses and R&D spending to increase as it expanded the bioprocessing business, product development, manufacturing capacity, and commercial capabilities. It stated existing cash was adequate for at least 24 months absent additional acquisitions.
- The filing provides no specific 2018 revenue or earnings guidance.
- Key risks include reliance on a limited number of customers (GE Healthcare and MilliporeSigma represented 21% and 18% of 2017 revenue), competition, dependence on qualified suppliers, execution and integration of acquisitions, and potential impairment of acquisition-related goodwill and intangible assets.
- Acquisition accounting materially increased goodwill and intangible assets: year-end goodwill was $327.3 million and net intangible assets $144.8 million. Spectrum’s purchase-price allocation remained preliminary in certain respects.
- Convertible-note conversion, repurchase, and cash-settlement terms may require significant cash or result in share dilution. Notes with $11,000 face value submitted for conversion in Q4 were settled in Q1 2018.
- Tax reform accounting was provisional under SEC guidance; the company recorded a $3.3 million transition-tax provision and a benefit from the lower federal rate. Management said estimates could be adjusted as calculations and guidance developed.
- The auditor gave an unqualified opinion on the financial statements and internal controls. Management’s internal-control assessment excluded Spectrum, acquired in 2017.
- The filing reports no legal proceedings believed likely to have a material adverse effect and no off-balance-sheet financing arrangements.
Important facts for investors to verify
- How much of reported growth is organic versus acquired, particularly for filtration and chromatography, and whether Spectrum integration delivers expected commercial benefits.
- Whether gross margins recover as acquisition-related inventory step-up effects and integration costs abate.
- The recurring earnings and cash-tax implications after separating the 2017 tax benefit, valuation-allowance releases, and tax-reform adjustments from operating performance.
- Customer concentration, renewal and performance of Protein A supply agreements, and progress in expanding direct sales.
- Cash generation and funding needs relative to the 2021 convertible notes, acquisition plans, and potential dilution.
- Goodwill and intangible-asset assumptions, the final Spectrum purchase-price allocation, and integration controls, including the acquired business excluded from the 2017 internal-control assessment.